Precision Targeting
Clinical Outcomes
Recent trials show synaptiq’s AI-guided TMS improves remission rates in depression compared to standard protocols.
FDA Pathway
Our rigorous FDA submission highlights safety and efficacy backed by multi-center clinical data.
Technology Overview
Synaptiq’s system integrates advanced AI algorithms with real-time neural targeting for effective treatment.
FDA Pathway
We collaborate with leading institutions to refine protocols and expand indications for AI-guided TMS.
About Us
At Synaptiq Neurotech, we develop AI-driven TMS solutions designed to enhance precision and improve patient outcomes in psychiatric care.
Our Mission
Precision Focus
Our Vision
Clinical Impact
Precision Targeting
AI-driven algorithms tailor TMS delivery to individual brain maps, enhancing treatment accuracy.
Clinical Outcomes
Robust data demonstrates improved patient response rates and sustained symptom relief.
Regulatory Path
Clear FDA pathways ensure compliance and safety for hospital integration.
Research Support
Ongoing clinical trials validate efficacy and refine treatment protocols.